29 April 2022
IntegraGen reports 2021 annual results with a strong growth of 20% in revenue from current operations and a significant profitability improvement

Évry, France, april 29TH 2022 – 6.00pm (…) »
29 April 2022
Évry, France, april 29TH 2022 – 6.00pm (…) »
14 January 2022
EVRY, FRANCE, FRIDAY 14 JANUARY 2021, 7.30 – IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), an OncoDNA group (…) »
16 July 2021
EVRY, FRANCE, FRIDAY 16 JULY 2021, 7.30AM – IntegraGen (FR0010908723 – ALINT (…) »
12 January 2021
IntegraGen announced today its unaudited business figures for the year 2020.
2020 revenue amounted to 9.0 M € versus 8.1 M € in 2019, an increase of 10% over 12 months. Increased sequencing services reported for company’s Evry lab and at outsourced platforms run by the company for the SeqOIA (…) »18 September 2020
IntegraGen has announced today its financial results for the first half of 2020 with the accounts having been reviewed by the Board of Directors on 17 September 2020.
Company posts positive operating performance (EBITDA) for the second consecutive semester, supported by revenue growth (+5%) and confirms (…) »
16 September 2020
This press release was prepared and distributed by OncoDNA S.A. in accordance with the provisions of Articles 231-27 1 ° and 2 ° and 231-28 of the general regulations of the Autorité des marchés financiers (the “AMF”).
01 September 2020
IntegraGen’s Combined General Assembly for 2020 will be held on September 17, 2020 at 2 p.m. at the company’s headquarters which is located at Génopole Campus 1,Genavenir 8, Porte 840, 5 rue Henri Desbruères – 91000 Evry, France
09 July 2020
Agreement to file a friendly takeover bid initiated by ONCODNA on INTEGRAGEN to acquire all outstanding shares at a price of 2.20€ per share. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of (…) »
09 July 2020
IntegraGen announced unaudited sales for the first half of 2020 were 4,706 k€, an increase of 13% compared to the first half of 2019 and 15% on a like-for-like basis taking into account the sale of the company’s diagnostic business at the start of 2020. The growth in sales (…) »
03 April 2020
+20% sales growth, positive gross operating surplus during second half of year, and close to break-even for the year
IntegraGen announced its financial results for the year ending December 31, 2019. The annual accounts were approved by the Board of Directors at a meeting held on April 2, 2020.
Operating (…) »